If you missed out of the great #NephJC chat this week you can catch-up with our rapid 10 tweet summary.
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
If you missed out of the great #NephJC chat this week you can catch-up with our rapid 10 tweet summary.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) August 3, 2022
To salt or not to salt? 🧂 That is the question in heart failure💔
✳️ 10 tweets #NephJC catch-up ✳️
Missed the SODIUM-HF trial discussed last week? Read on for a snapshot of this RCT of dietary sodium reduction in patients with heart failure! pic.twitter.com/mk5D8YAvwF